Analysis of Technological Developments in the Treatment of Alzheimer’s Disease through Patent Documents


Population aging and the consequent change in the profile of the age pyramid are already a reality the world over. One undeniable effect of this aging process is the significant increase in the number of people with Alzheimer’s disease (AD), which is the most common form of dementia, accounting for around 50% - 60% of all cases. AD tends to affect people in their 60 s, becoming progressively more commonplace in older age groups. It is an incurable disease, and patients can live for many years taking medication on a daily basis. This study shows that research into AD is on the rise around the world because the pharmaceutical industry and research institutions are seeking new types of drugs to treat and even cure Alzheimer’s patients. By analyzing patent documents, we map out the potential future treatments for this disease, indicating the leading countries and drugs companies that have invested most in a bid to accelerate progress towards new discoveries about the disease and the development of new drugs.

Share and Cite:

Carvalho, K. , Winter, E. and Souza Antunes, A. (2015) Analysis of Technological Developments in the Treatment of Alzheimer’s Disease through Patent Documents. Intelligent Information Management, 7, 268-281. doi: 10.4236/iim.2015.75022.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Prince, M., Bryce, R., Albanese, E., Wimo, A., Ribeiro, W. and Cleusa, P. (2013) The Global Prevalence of Dementia: A Systematic Review and Meta-Analysis. Alzheimer’s and Dementia, 9, 63-75.
[2] United Nations (2014) World Population Prospects: The 2010 Revision.
[3] de Vellis, J. (2014) Alzheimer’s Disease International.
[4] Barnes, D. and Yaffe, K. (2011) The Projected Impact of Risk Factor Reduction on Alzheimer’s Disease Prevalence. Lancet Neurology, 10, 819-828.
[5] National Institute on Aging.
[6] (2010) Alzheimer’s Disease International.
[7] Wippold, F.J., Cairns, N., Vo, K., Holtzman, D.M. and Morris, J.C. (2008) Neuropathology for the Neuroradiologist: Plaques and Tangles. American Journal of Neuroradiology, 29, 18-22.
[8] Tiraboschi, P., Hansen, L.A., Thal, L.J. and Corey-Bloom, J. (2004) The Importance of Neuritic Plaques and Tangles to the Development and Evolution of AD. Neurology, 62, 1984-1989.
[9] Ittner, L.M. and Götz, J. (2011) Amyloid-β and Tau—A Toxic pas de deux in Alzheimer’s Disease. Nature Reviews Neuroscience, 12, 67-72.
[10] Qiu, C., Kivipelto, M. and von Strauss, E. (2009) Epidemiology of Alzheimer’s Disease: Occurrence, Determinants, and Strategies toward Intervention. Dialogues in Clinical Neuroscience, 11, 111-128.
[11] Shankar, G.M., Bloodgood, B.L., Townsend, M., Walsh, D.M., Selkoe, D.J. and Sabatini, B.L. (2007) Natural Oligomers of the Alzheimer Amyloid-β Protein Induce Reversible Synapse Loss by Modulating an NMDA-Type Glutamate Receptor-Dependent Signaling Pathway. The Journal of Neuroscience, 27, 2866-2875.
[12] Desai, A.K. and Chand, P. (2009) Tau-Based Therapies for Alzheimer’s Disease: Wave of the Future. Primary Psychiatry, 16, 40-46.
[13] Kolarova, M., García-Sierra, F., Bartos, A., Ricny, J. and Ripova, D. (2012) Structure and Pathology of Tau Protein in Alzheimer Disease. International Journal of Alzheimer’s Disease, 2012, 1-13.
[14] Tuneu Valls, L., Cano, M.R., Marquillas, M.S., Pérez, E.P. and Franco, A.G. (2015) Guía de seguimiento farmaco-terapéutico de los pacientes con Alzheimer.
[15] Williams, D.R. (2006) Tauopathies: Classification and Clinical Update on Neurodegenerative Diseases Associated with Microtubule-Associated Protein Tau. Internal Medicine Journal, 36, 652-660.
[16] Ferri, C.P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., et al. (2006) Global Prevalence of Dementia: A Delphi Consensus Study. The Lancet, 366, 2112-2117.
[17] Brookmeyer, R., Johnson, E., Ziegler-Graham, K. and Arrighi, H.M. (2007) Forecasting the Global Burden of Alzheimer’s Disease. Alzheimer’s & Dement, 3, 186-191.
[18] Spuch, C., Saida, O. and Navarro, C. (2012) Advances in the Treatment of Neurodegenerative Disorders Employing Nanoparticles. Recent Patents on Drug Delivery & Formulation, 6, 2-18.
[19] Food and Drug Administration.
[20] Romero, A., Cacabelos, R., Oset-Gasque, M.J., Samadi, A. and Marco-Contelles, J. (2013) Novel Tacrine-Related Drugs as Potential Candidates for the Treatment of Alzheimer’s Disease. Bioorganic & Medicinal Chemistry Letters, 23, 1916-1922.
[21] Watkins, P.B., Zimmerman, H.J., Knapp, M.J., Gracon, S.I. and Lewis, K.W. (1994) Hepatotoxic Effects of Tacrine Administration in Patients with Alzheimer’s Disease. Jama, 271, 992-998.
[22] Johnson, J.W. and Kotermanski, S.E. (2006) Mechanism of Action of Memantine. Current Opinion in Pharmacology, 6, 61-67.
[23] Tetsuya, K., Daniel, J., Jihoon Jo, W., Regan, P., Piers, T., et al. (2014) Microtubule-Associated Protein Tau Is Essential for Long-Term Depression in the Hippocampus. Philosophical Transactions of the Royal Society B: Biological Sciences, 369, 20130144.
[24] Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P. and Kivipelto, M. (2010) Alzheimer’s Disease: Clinical Trials and Drug Development. The Lancet Neurology, 9, 702-716.
[25] Hurd, M.D., Martorell, P., Delavande, A., Mullen, K.J. and Langa, K.M. (2013) Monetary Costs of Dementia in the United States. New England Journal of Medicine, 368, 1326-1334.
[26] Alzheimer’s Association (2015) Alzheimer’s Disease Facts and Figures. Alzheimer’s & Dementia, 11, 1-83.
[27] Umira, S.A. (2015) “Alzheimer” an Ambiguous Ailment; a Comprehensive Review. Research & Reviews: A Journal of Pharmaceutical Science, 5, 8-16.
[28] Huang, Y. and Mucke, L. (2012) Alzheimer Mechanisms and Therapeutic Strategies. Cell, 148, 1204-1222.
[29] Israel, M.A., Yuan, S.H., Bardy, C., Reyna, S.M., Ma, Y., et al. (2012) Probing Sporadic and Familial Alzheimer’s Disease Using Induced Pluripotent Stem Cells. Nature, 482, 216-220.
[30] Lindvall, O. and Kokaia, Z. (2006) Stem Cells for the Treatment of Neurological Disorders. Nature, 441, 1094-1096.
[31] Yagi, T., Ito, D., Okada, Y., Akamatsu, W., Nihei, Y., et al. (2011) Modeling Familial Alzheimer’s Disease with Induced Pluripotent Stem Cells. Human Molecular Genetics, 20, 4530-4539.
[32] Lee, H.J., Lee, J.K., Lee, H., Shin, J.W., Carter, J.E., Sakamoto, T., Jin, H.K. and Bae, J.S. (2010) The Therapeutic Potential of Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells in Alzheimer’s Disease. Neuroscience Letters, 481, 30-35.
[33] Lindvall, O. and Kokaia, Z. (2010) Stem Cells in Human Neurodegenerative Disorders—Time for Clinical Translation? The Journal of Clinical Investigation, 120, 29.
[34] Müller, F.J., Snyder, E.Y. and Loring, J.F. (2006) Gene Therapy: Can Neural Stem Cells Deliver? Nature Reviews Neuroscience, 7, 75-84.
[35] Tuszynski, M.H. and Blesch, A. (2004) Nerve Growth Factor: From Animal Models of Cholinergic Neuronal Degeneration to Gene Therapy in Alzheimer’s Disease. Progress in Brain Research, 146, 439-449.
[36] Nagahara, A.H., Merrill, D.A., Coppola, G., Tsukada, S., Schroeder, B.E., et al. (2009) Neuroprotective Effects of Brain-Derived Neurotrophic Factor in Rodent and Primate Models of Alzheimer’s Disease. Nature Medicine, 15, 331-337.
[37] Macdonald, A., Briggs, K., Poppe, M., Higgins, A., Velayudhan, L. and Lovestone, S. (2008) A Feasibility and Tolerability Study of Lithium in Alzheimer’s Disease. International Journal of Geriatric Psychiatry, 23, 704-711.
[38] Toledo, E.M. and Inestrosa, N.C. (2010) Activation of Wnt Signaling by Lithium and Rosiglitazone Reduced Spatial Memory Impairment and Neurodegeneration in Brains of an APPswe/PSEN1ΔE9 Mouse Model of Alzheimer’s Disease. Molecular Psychiatry, 15, 272-285.
[39] Forlenza, O.V., De-Paula, V.D.J.R. and Diniz, B.S.O. (2014) Neuroprotective Effects of Lithium: Implications for the Treatment of Alzheimer’s Disease and Related Neurodegenerative Disorders. ACS Chemical Neuroscience, 5, 443-450.
[40] Wolozin, B., Wang, S.W., Li, N.C., Lee, A., Lee, T.A. and Kazis, L.E. (2007) Simvastatin Is Associated with a Reduced Incidence of Dementia and Parkinson’s Disease. BMC Medicine, 5, 20.
[41] Shepardson, N.E., Shankar, G.M. and Selkoe, D.J. (2011) Cholesterol Level and Statin Use in Alzheimer Disease: II. Review of Human Trials and Recommendations. Archives of Neurology, 68, 1385-1392.
[42] Kandiah, N. and Feldman, H.H. (2009) Therapeutic Potential of Statins in Alzheimer’s Disease. Journal of the Neurological Sciences, 283, 230-234.
[43] Lemere, C.A. (2009) Developing Novel Immunogens for a Safe and Effective Alzheimer’s Disease Vaccine. Progress in Brain Research, 175, 83-93.
[44] Wisniewski, T. and Konietzko, U. (2008) Amyloid-β Immunisation for Alzheimer’s Disease. The Lancet Neurology, 7, 805-811.
[45] Davtyan, H. and Konietzko, U. (2013) Immunogenicity, Efficacy, Safety, and Mechanism of Action of Epitope Vaccine (Lu AF20513) for Alzheimer’s Disease: Prelude to a Clinical Trial. The Journal of Neuroscience, 33, 4923-4934.
[46] Rottkamp, C.A., Nunomura, A., Raina, A.K., Sayre, L.M., Perry, G. and Smith, M.A. (2000) Oxidative Stress, Antioxidants, and Alzheimer Disease. Alzheimer Disease & Associated Disorders, 14, S62-S66.
[47] Galasko, D.R., Peskind, E., Clark, C.M., Quinn, J.F., Ringman, J.M., Jicha, G.A. and Aisen, P. (2012) Antioxidants for Alzheimer Disease: A Randomized Clinical Trial with Cerebrospinal Fluid Biomarker Measures. Archives of Neurology, 69, 836-841.
[48] Rege, S.D., Geetha, T., Broderick, T.L. and Ramesh Babu, J. (2015) Resveratrol Protects β Amyloid-Induced Oxidative Damage and Memory Associated Proteins in H19-7 Hippocampal Neuronal Cells. Current Alzheimer Research, 12, 147-156.
[49] Pillai, R., Uyehara-Lock, J.H. and Bellinger, F.P. (2014) Selenium and Selenoprotein Function in Brain Disorders. IUBMB Life, 66, 229-239.
[50] de Oliveira, B.F., Veloso, C.A., Nogueira-Machado, J.A., de Moraes, E.N., dos Santos, R.R., Cintra, M.T.G. and Chaves, M.M. (2012) Ascorbic Acid, Alpha-Tocopherol, and Beta-Carotene Reduce Oxidative Stress and Proinflammatory Cytokines in Mononuclear Cells of Alzheimer’s Disease Patients. Nutritional Neuroscience, 15, 244-251.
[51] Mangialasche, F., Kivipelto, M., Mecocci, P., Rizzuto, D., Palmer, K., Winblad, B. and Fratiglioni, L. (2010) High Plasma Levels of Vitamin E Forms and Reduced Alzheimer’s Disease Risk in Advanced Age. Journal of Alzheimer’s Disease, 20, 1029-1037.
[52] Carroll, J.C., Rosario, E.R., Chang, L., Stanczyk, F.Z., Oddo, S., LaFerla, F.M. and Pike, C.J. (2007) Progesterone and Estrogen Regulate Alzheimer-Like Neuropathology in Female 3xTg-AD Mice. The Journal of Neuroscience, 27, 13357-13365.
[53] Lee, J.H., Jiang, Y., Han, D.H., Shin, S.K., Choi, W.H. and Lee, M.J. (2014) Targeting Estrogen Receptors for the Treatment of Alzheimer’s Disease. Molecular Neurobiology, 49, 39-49.
[54] Vest, R.S. and Pike, C.J. (2013) Gender, Sex Steroid Hormones, and Alzheimer’s Disease. Hormones and Behavior, 63, 301-307.
[55] Xia, W. (2001) Amyloid Metabolism and Secretases in Alzheimer’s Disease. Current Neurology and Neuroscience Reports, 1, 422-427.
[56] Holsinger, R.M., McLean, C.A., Beyreuther, K., Masters, C.L. and Evin, G. (2002) Increased Expression of the Amyloid Precursor β—Secretase in Alzheimer’s Disease. Annals of Neurology, 51, 783-786.
[57] Yan, R. and Vassar, R. (2014) Targeting the β Secretase BACE1 for Alzheimer’s Disease Therapy. The Lancet Neurology, 13, 319-329.
[58] Maiti, P., Manna, J., Veleri, S. and Frautschy, S. (2014) Molecular Chaperone Dysfunction in Neurodegenerative Diseases and Effects of Curcumin. BioMed Research International, 2014, Article ID: 495091.
[59] Ono, K., Hasegawa, K., Naiki, H., Naiki and Yamada, M. (2004) Curcumin Has Potent Anti-Amyloidogenic Effects for Alzheimer’s β-Amyloid Fibrils in Vitro. Journal of Neuroscience Research, 75, 742-750.
[60] Hamaguchi, T., Ono, K. and Yamada, M. (2010) Review: Curcumin and Alzheimer’s Disease. CNS Neuroscience & Therapeutics, 16, 285-297.
[61] Lim, G.P., Calon, F., Morihara, T., Yang, F., Teter, B., Ubeda, O. and Cole, G.M. (2005) A Diet Enriched with the Omega-3 Fatty Acid Docosahexaenoic Acid Reduces Amyloid Burden in an Aged Alzheimer Mouse Model. The Journal of Neuroscience, 25, 3032-3040.
[62] Calon, F., Lim, G. P., Yang, F., Morihara, T., Teter, B., Ubeda, O. and Cole, G.M. (2004) Docosahexaenoic Acid Protects from Dendritic Pathology in an Alzheimer’s Disease Mouse Model. Neuron, 43, 633-645.
[63] Hashimoto, M., Hossain, S., Katakura, M., Al Mamun, A. and Shido, O. (2015) The Binding of Aβ 1-42 to Lipid Rafts of RBC Is Enhanced by Dietary Docosahexaenoic Acid in Rats: Implicates to Alzheimer’s Disease. Biochimica et Biophysica Acta (BBA)-Biomembranes, 1848, 1402-1409.
[64] Qing, H., He, G., Ly, P.T., Fox, C.J., Staufenbiel, M., Cai, F. and Song, W. (2008) Valproic Acid Inhibits Aβ Production, Neuritic Plaque formation, and Behavioral Deficits in Alzheimer’s Disease Mouse Models. The Journal of Experimental Medicine, 205, 2781-2789.
[65] Smith, A.M., Gibbons, H.M. and Dragunow, M. (2010) Valproic Acid Enhances Microglial Phagocytosis of Amyloid-β 1-42. Neuroscience, 169, 505-515.
[66] Ziyatdinova, S., Viswanathan, J., Hiltunen, M., Tanila, H. and Pitkänen, A. (2015) Reduction of Epileptiform Activity by Valproic Acid in a Mouse Model of Alzheimer’s Disease Is Not Long-Lasting after Treatment Discontinuation. Epilepsy Research, 112, 43-55.
[67] Dekosky, S.T., Williamson, J.D., Fitzpatrick, A.L., Kronmal, R.A., Ives, D.G., Saxton, J.A., et al. (2008) Ginkgo Biloba for Prevention of Dementia: A Randomized Controlled Trial. Jama, 300, 2253-2262.
[68] Vellas, B., Coley, N., Ousset, P.J., Berrut, G., Dartigues, J.F. and Dubois, B., GuidAge Study Group (2012) Long-Term Use of Standardised Ginkgo Biloba Extract for the Prevention of Alzheimer’s Disease (GuidAge): A Randomised Placebo-Controlled Trial. The Lancet Neurology, 11, 851-859.
[69] Ude, C., Schubert-Zsilavecz, M. and Wurglics, M. (2013) Ginkgo Biloba Extracts: A Review of the Pharmacokinetics of the Active Ingredients. Clinical Pharmacokinetics, 52, 727-749.

Copyright © 2022 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.